CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of CJC-1295 DAC is 6-8 days. This means dosing once or twice weekly is typical to maintain stable levels. The half-life directly affects how long CJC-1295 DAC remains active and influences optimal injection timing.
What Is the Half-Life of CJC-1295 DAC?
The half-life of CJC-1295 DAC is 6-8 days. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer CJC-1295 DAC to maintain therapeutic blood levels.
What Does CJC-1295 DAC's Half-Life Mean for Dosing?
With a half-life of 6-8 days, CJC-1295 DAC requires dosing once or twice weekly to maintain stable levels. The standard dosage of 1-2 mg per injection via subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, CJC-1295 DAC reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For CJC-1295 DAC, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject CJC-1295 DAC?
Optimal timing depends on your research goals. A half-life of 6-8 days means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (once or twice weekly) for more stable levels throughout the day.
How Does CJC-1295 DAC's Half-Life Compare to Similar Peptides?
CJC-1295 DAC is a GHRH analog with extended half-life. Its half-life of 6-8 days positions it with a longer duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →Bottom Line: CJC-1295 DAC Half-Life and Dosing
CJC-1295 DAC has a half-life of 6-8 days, supporting the standard protocol of 1-2 mg per injection dosed once or twice weekly over 12-16 weeks.
Read our CJC-1295 DAC dosage guide for complete protocol details.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Benefits
- CJC-1295 DAC Side Effects
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 DAC Research
Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.